Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression

Journal of Pharmacological Sciences

Volumn 110, Issue 1, 2009, Pages 98-104

  Vezmar, Sandra ^a   Miljković, Branislava ^a   Vučićević, Katarina ^a   Timotijević, Ivana ^a   Prostran, Milica ^a   Todorović, Zoran ^a   Pokrajac, Milena ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Amitriptyline; Efficacy; Fluvoxamine; Interaction; Safety

Indexed keywords

AMITRIPTYLINE; FLUVOXAMINE; NORTRIPTYLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; WEAKNESS; XEROSTOMIA;

EID: 66349112356     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09013FP     Document Type: Article

References (46)

1. Ballas C, Staab JP, Evans DL. Strategies for treatment-resistant depression. Psychopharmacol Bull. 2002;36:39-62.
2. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine- XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
3. Horgan DP. Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? Med J Aust. 2007;187:199-200.
4. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry. 1989;50:447-449. (Pubitemid 20024293)
5. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307.
6. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992;161:562-565.
7. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol. 1988;154:125-134. (Pubitemid 18221197)
8. Ohashi S, Togashi H, Matsumoto M, Mori K, Ueno K, Yoshioka M. Changes in synaptic properties in cortical-limbic communications induced by repeated treatments with fluvoxamine in rats. J Pharmacol Sci. 2003;92:100-107. (Pubitemid 36833455)
9. Fujishiro J, Imanishi T, Baba J, Kosaka K. Comparison of noradrenergic and serotonergic antidepressants in reducing immobility time in the tail suspension test. J Pharmacol Sci. 2001;85:327-330. (Pubitemid 32293961)
10. Keks NA, Burrows GD, Copolov DL, Newton R, Paoletti N, Schweitzer I, et al. Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? Med J Aust. 2007;186:142-144.
11. Maskall DD, Lam RW. Increased plasma concentration of imipramine following augmentation with fluvoxamine. Am J Psychiatry. 1993;150:1566. (Pubitemid 23289329)
12. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31:347-353.
13. Härtter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology. 1993;110:302-308. (Pubitemid 23051131)
14. Seifritz E, Holsboer-Trachsler E, Hemmeter U, Eap CB, Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol. 1994;4:15-20. (Pubitemid 24087022)
15. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98. (Pubitemid 24120706)
16. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15:243-246. (Pubitemid 23171910)
17. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34:262-265.
18. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-131.
19. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet. 1995;29 Suppl 1:10-18.
20. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier- Perey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit. 1992;14:1-8.
21. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry. 1988;145:1478. (Pubitemid 18267397)
22. Kahn DG. Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine. J Clin Psychiatry. 1990;51:36. (Pubitemid 20042568)
23. Peyre F, Verdoux H, Bourgeois M. Fluvoxamine. Study of treatment effect on a group of 189 hospitalized patients with depression. Encephale. 1992;18:73-74.
24. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry. 1996;153:414-416. (Pubitemid 26074720)
25. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-1214. (Pubitemid 23098317)
26. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1994;27:175-190. (Pubitemid 24280231)
27. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444-469. (Pubitemid 26415952)
28. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, et al. Comparison of full-dose versus halfdose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord. 1993;27:139-145. (Pubitemid 23080331)
29. Miljkovic B, Pokrajac M, Timotijevic I, Varagic V. Solid-phase extraction and high performance liquid chromatographic determination of amitriptyline and nortriptyline in human plasma. J Liq Chrom Relat Tech. 1997;20:1067-1078. (Pubitemid 27174396)
30. Miljkovic BR, Pokrajac M, Timotijevic I, Varagic V. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine- lithium therapy. Int Clin Psychopharmacol. 1997;12:207-212. (Pubitemid 27414634)
31. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001
32. Miljkovic B, Pokrajac M, Timotijevic I, Varagic V. Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients. Eur J Drug Metab Pharmacokinet. 1996;21:251-255. (Pubitemid 27032514)
33. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry. 1991;52 Suppl:23-33.
34. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al; Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
35. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998;38:112-121. (Pubitemid 28117366)
36. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19:155-163. (Pubitemid 29161961)
37. Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet. 1987;13:381-392.
38. Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem. 2005;51:376-385. (Pubitemid 40175808)
39. Kasper S, Fuger J, Möller HJ. Comparative efficacy of antidepressants. Drugs. 1992;43:11-22.
40. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36. (Pubitemid 30173208)
41. Gasperini M, Gatti F, Bellini L, Anniverno R, Smeraldi E. Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine. A double-blind study in depressed inpatients. Neuropsychobiology. 1992;26:186-192.
42. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374. (Pubitemid 24281764)
43. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22:379-387. (Pubitemid 34810327)
44. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154:963-969. (Pubitemid 27274539)
45. Beasley CM Jr, Bosomworth JC, Wernicke JF. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull. 1990;26:18-24. (Pubitemid 20322241)
46. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55:296-300. (Pubitemid 38117167)